SynthesisJournal of gastroenterology and hepatology2026
Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
Synthesis in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic Resistance Heterogeneity as an Unmeasured Confounder in Tegoprazan-Amoxicillin Dual Therapy Meta-Analysis.Journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotic resistance undermines conventional Helicobacter pylori (H. pylori) eradication therapies. Tegoprazan-amoxicillin (TA) dual therapy is a promising alternative, but its efficacy and safety compared with other treatment regimens remain unclear. The aim of this meta-analysis was to comprehensively evaluate the efficacy and safety of TA dual therapy in eradicating H. pylori.
methodsPubMed, Embase, CENTRAL, and Web of Science were searched from inception to December 2025. Eligible randomized controlled trials (RCTs) compared TA dual therapy with bismuth-containing quadruple therapy (BQT) or proton pump inhibitor (PPI)-based high-dose dual therapy (PPI-HDDT) in adults with H. pylori infection. The outcomes were H. pylori eradication rate, adverse events, and medication adherence. Evidence quality was assessed via GRADE.
resultsSix RCTs (n = 1909) were included. TA dual therapy showed no significant difference in eradication rate compared with BQT (n = 5 RCTs, ITT analysis: 78.0% vs. 81.4%, RR = 0.97, 95% CI: 0.88-1.05, p = 0.44; PP analysis: 84.6% vs. 86.2%, RR = 0.96, 95% CI: 0.87-1.06, p = 0.39; low-quality evidence), confirmed by trial sequential analysis. TA dual therapy had a lower overall adverse event rate (11.3% vs. 22.5%, RR = 0.50, 95% CI: 0.37-0.67, p < 0.00001; moderate-quality evidence) but similar adherence (95.7% vs. 94.5%, RR = 1.01, 95% CI: 0.99-1.03, p = 0.31; moderate-quality evidence) compared with BQT. Efficacy and safety were comparable between TA dual therapy and PPI-HDDT (n = 1 RCT).
conclusionsThe TA dual therapy exhibits similar efficacy compared with BQT and PPI-HDDT for H. pylori eradication, with a better safety profile compared with BQT. However, its overall eradication efficacy is suboptimal, necessitating further regimen optimization in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.